Synchronous bilateral testis cancer (SBTC) is a rare event. It represents only 0.5–1% of all new cases of testicular cancer. Patients with this disease require careful management for psychological, oncological, and medical problems.

We performed a PubMed search for all series that reported SBTC. We considered only articles in English, reporting on more than three cases. We also performed an analysis of the reported evidence regarding testosterone replacement and surgical treatment. We found 10 studies satisfying inclusion criteria for a total of 73 patients. The majority are bilateral seminoma, which present with a low stage at diagnosis, and mixed histology tumours, both with a good overall survival. On the other hand, cases with bilateral non-seminoma histology are associated with poor prognosis and high stage at presentation.

Testis-sparing surgery should be an eligible choice in selected cases, to preserve fertility and avoid testosterone deficiency. Multiple biopsies are recommended in these patients, and in the case of intratubular germ cell neoplasia (ITGCN) presence, scrotal radiotherapy is mandatory. Subcutaneous testosterone pellets guarantee higher patient acceptance and physiological testosterone levels. Lifelong follow-up and psychological support, with special care for infertility and erectile dysfunction, must be considered in this cohort of patients.

Key words: synchronous bilateral testicular tumour, survival, quality of life, treatment, androgen substitution.

Synchronous bilateral testis cancer: clinical and oncological management

Davide Campobasso¹, Stefania Ferretti², Antonio Frattini²

¹Urology OU, Civil Hospital of Guastalla, AUSL of Reggio Emilia, Guastalla (RE), Italy
²Urology OU, Surgical Department, University Hospital of Parma, Parma, Italy

Introduction

Testicular cancer is the most common solid malignancy in men between the ages of 15 and 40 years, representing 2–3% of all male cancers, with 3–6 new cases occurring per 100,000 males/per year in Western countries. Testicular germ-cell tumours, seminomas (SGCT) and non-seminomas (NSGCT), are the most frequent, with a peak incidence occurring in the fourth decade of life for pure seminoma and in the third decade of life for non-seminoma [1]. The incidence of bilateral testicular tumours, which is estimated to be around 2–5%, is rare [2, 3]. Approximately 65–75% of these bilateral tumours are metachronous [4, 5]. The majority are seminomas, and they are histologically almost always identical [6–8]. Patients with bilateral testicular tumours, synchronous or metachronous, present with different problems requiring careful management to permit a good quality of life. Here we review the literature on oncological outcome and management of synchronous bilateral testis cancer (SBTC), with specific emphasis on epidemiology, risk factors, and long-term sequelae in survivors.

Material and methods

In 1988 Dieckmann et al. [6], after a revision of the literature, reported a total of 151 cases of bilateral synchronous cancer, and 114 of these (75.5%) demonstrated seminoma in both testicles. By contrast, other authors reported an inversion of the incidence in the last years [4, 9].

In a review of cancer registries of the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program [5] for testis cancer, the authors estimated a prevalence of 0.6% (175 of 29,515) for synchronous bilateral testicular cancer. In 45% (61 of 135) of those in which the extent of the disease was known there was a regional or distant localisation, with a 10-year overall survival rate in 85% of all patients. In this article the incidence of bilateral seminoma was 50% (88 of 175) with 34% (59 of 175) of patients having discordant histology. This data is confirmed in other series [3, 4, 6, 9, 10].

Additionally, synchronous tumours were metastatic at presentation [2, 3, 5, 9].

The studies by Holzbeierlein et al. [4] and by the National Institute of Oncology in Hungary [11] represent an exception because they report that most patients in the synchronous tumour group presented with low-stage disease, respectively, 60% (6 of 10) and 68% (13 of 19).

In the literature bilateral synchronous testis cancer are reported as isolated case reports or small series.

We performed a PubMed search for all English language publications with the following quest terms: bilateral testicular cancer, bilateral testicular germ cell tumour, and bilateral testicular neoplasm. Inclusion criteria comprise: series with more than three patients and containing relevant information about clinical and oncological features in relation to histology and stage. We identified 13 studies with more than three cases of SBTC [2–5, 9,
10, 12–18], but only 10 of them [2–4, 9, 10, 13, 15, 16, 18] described separately the different outcomes of SBTC with distinction based on histology and stage.

The major series reported in the literature and their results can be seen in Table 1.

Akdogan et al. [2] reviewed patients treated for bilateral testicular cancer in two tertiary centres in Turkey with six cases of synchronous cancer. Two of these had seminoma histology on both sides, the remaining had non-seminoma histology. All six patients had metastatic disease at presentation (stage III). They were treated with chemotherapy, and no evidence of disease was found at the last follow-up with a minimum length of 41 months.

Klatte et al. [3] reported six patients with synchronous bilateral testicular cancer. Four patients presented with synchronous seminoma, two stage I, and two stage II (retroperitoneal lymph nodes), three underwent radiotherapy, and the fourth (stage I) developed lymph nodes retroperitoneal recurrence after 18 months and received chemotherapy. The two discordant histology cases were seminoma and mixed germ cell tumour with stage II and III (retroperitoneal lymph nodes and lung metastasis, respectively), both treated with chemotherapy and retroperitoneal lymph node dissection. All patients were alive after a median follow-up of 121 months.

Holzbeierlein et al. [4] reviewed the experience of the Memorial Sloan Kettering Cancer Centre with 10 cases of synchronous bilateral tumours. Only in three cases histology was concordant (bilateral seminoma). Retroperitoneal lymph node dissection was performed in four patients with discordant histology (three stage I, one stage II); chemotherapy in three patients (two stage II, one stage III), one with bilateral seminoma (stage II), radiotherapy in two seminoma (stage I), and one patient preferred surveillance protocol (stage I). After a median follow-up of 29.5 months no patient had had a recurrence.

Hentrich et al. [5] reported 14 cases of synchronous testis cancer. Concordant histology was present in seven cases (four seminoma, three non-seminoma). Radiotherapy was performed in three bilateral seminoma (one stage I and two stage II) with one case of stage II relapsing after 28 months, being treated with chemotherapy but dying after one month. The remaining bilateral seminoma (stage I) was treated with chemotherapy and he was alive after 46 months. Six patients with discordant histology were treated with only chemotherapy, one patient (stage III) died after 40 months for neutropenic sepsis, while at a median follow-up of 28.5 months the remaining bilateral SGCT had no evidence of disease. The other case with discordant histology in stage I, underwent retroperitoneal lymph node dissection and was still alive after 76 months. The three non-seminomas concordant histology were all in stage III disease, they received chemotherapy but died after a median of 18.8 months (range 0.5–32).

In the series of Indiana University, reviewed in 1998 [10], there were five cases of synchronous testis cancer, three bilateral seminoma (two stage I treated with radiotherapy and one stage II treated with chemotherapy) with no evidence of disease after a median follow-up of 17 months, one bilateral stage III teratoma, who underwent post-chemotherapy retroperitoneal lymph node dissection and was still alive after 168 months and one case with stage II discordant histology, with no evidence of disease after chemotherapy.

The Anderson Cancer Centre reported in 2002 [11] four cases of synchronous bilateral germ cell tumours, with one case of discordant histology in stage III treated with chemotherapy dying after 41 months, the remaining cases were bilateral seminoma in stage I undergoing chemotherapy and being alive after 18 and 27 months, respectively.

Tomita et al. [12] in 2007 described six cases, all of whom had concordant histology with five bilateral seminoma; three out of five (two stage I and one stage II) were treated with conservative chemotherapy (three cycles of bleomycin, etoposide, and cisplatin) with one testis preservation, no evidence of disease was revealed after 82 months and two years, respectively. The other two (stage I and II) underwent bilateral orchiectomy and chemotherapy with the same regimen, and no evidence of disease was observed after 86 and 23 months, respectively. The only bilateral stage III non-seminoma died after 11 months.

A multicentre report reviewed seven cases [15]: three bilateral seminoma (two stage I and one stage II), who received radiotherapy, both stage I were alive after six and three years, whereas the stage II case developed metastatic recurrence after 6.5 years and died; one case of bilateral non-seminoma, stage III disease died after one year; three cases with discordant histology, all of them being stage II, one of these underwent retroperitoneal lymph node dissection and was alive after two years, the other two received chemotherapy with no evidence of disease after one and four years.

In 1995 Heidenreich et al. [16] presented their experience with testis-sparing surgery in bilateral testicular cancer. In their series there were five synchronous tumours. In three cases they performed a conservative approach. Two of them had discordant histology (stage I and II), while the discordant histology cases were bilateral seminoma in two cases (stage I) and bilateral teratoma in one (stage I). All the patients had no evidence of disease with a median follow-up of 67 months (range 42–145 months).

The last article in order of time is reported by Ferretti et al. [18], who described their results in 11 patients with SBTC undergoing testis-sparing surgery, of whom one was lost to follow-up. In their series four cases underwent subsequent radical orchiectomy (massive TIN, positive surgical margin, rete testis invasion, recurrence after two years). Lymphadenectomy and chemotherapy were performed in the two patients with bilateral NSGCT stage II. In two patients with bilateral seminoma scrotal radiotherapy was performed, and three were treated with chemotherapy (two bilateral seminoma and one mixed histology). After a mean follow-up of 53.7 months, all patients are free from any recurrence with no need of hormonal substitution.

In summary, from a total of 73 patients were recorded, with the exclusion of two cases of bilateral Leydig cell tumour, 60.5% (44/71) had a discordant histology. Of these, 75% (33/44) were bilateral seminoma. In most cases (69.7%, 23/33) bilateral SGCT was diagnosed at stage
![Image of page content]

**Table 1. Major series reported in the literature**

| Author                  | Histology          | Stage      | Follow up (months) |
|-------------------------|--------------------|------------|--------------------|
| Akdogan et al. [2]      | 1 SS               | All stage III | NED                |
|                         | 2 NSNS (Ter/Ter)   |            | Minimum follow up 41 |
|                         | 3 Mx               |            |                    |
| Klatte et al. [3]       | 4 SS               | 2 STG I    | 24 & 70 NED        |
|                         | 2 Mx               | 1 STG II   | 191 & 118 NED      |
|                         |                    | 1 STG III  | 205 NED            |
|                         |                    |            | 124 NED            |
| Holzbeierlein et al. [4]| 3 SS               | 2 STG I    | NED                |
|                         | 7 Mx               | 1 STG II   | Median follow up 60 |
|                         |                    | 4 STG I    |                    |
|                         |                    | 2 STG II   |                    |
|                         |                    | 1 STG III  |                    |
| Hentrich et al. [9]     | 4 SS               | 2 STG I    | 6 & 46 NED         |
|                         | 3 NSNS             | 2 STG II   | 47 NED; 29 DOD     |
|                         | 7 Mx               | 3 STG III  | 0.5 & 32 DOD       |
|                         |                    | 1 STG I    | 22 & 7 & 6 NED     |
|                         |                    | 3 STG II   | 67 & 4 & 31 NED    |
|                         |                    | 1 STG III  | 40 NED             |
| Coogan et al. [10]      | 3 SS               | 2 STG I    | 22 & 9 NED         |
|                         | 1 NSNS (Ter/Ter)   | 1 STG II   | 20 NED             |
|                         | 1 Mx               | STG III    | 113 NED            |
|                         |                    | STG II     |                    |
| Che et al. [12]         | 3 SS               | 3 STG I    | 27 & 27 & 18 NED   |
|                         | 1 Mx (S/Ca Emb)    | 2 STG II   | 41 DOD             |
|                         |                    | 1 NSNS (Ca Emb/Ca Emb) | 86 & 82 & 24 NED |
|                         |                    | 3 STG I    | 23 & 24 NED        |
|                         |                    | STG III    | 11 DOD             |
| Tomita et al. [13]      | 5 SS               | 2 STG I    | 36 & 72 NED        |
|                         | 1 NSNS (Ca Emb/Ca Emb) | 1 STG II   | 78 NED             |
|                         |                    | STG III    | 12 DOD             |
|                         |                    |            | 24 & 48 & 6 NED    |
| Redmond et al. [15]     | 3 SS               | 2 STG I    | 145 & 59 NED       |
|                         | 1 NSNS             | 1 STG II   | 45 NED             |
|                         | 3 Mx               | STG III    | 45 NED             |
|                         |                    |            | 42 NED             |
| Heidenreich et al. [16] | 2 SS               | 2 STG I    | 5 STG I            |
|                         | 1 NSNS (Ter/Ter)   | 1 STG II   | 32 & 108 & 95 & 14 & 20 |
|                         | 1 Mx (S/Ca Emb)    | STG II     | 62 & 120 All       |
|                         |                    | STG I      | 9 & 69 NED         |
|                         |                    | 1 Bil Leydig cell tumour | 106 |
| Ferretti et al. [18]    | 5 SS               | 2 STG II   |                    |
|                         | 2 NSNS             | 2 STG I    |                    |
|                         | 2 Mx (N/S/ Epid Cyst) | 1 STG I   |                    |
|                         | 1 Bil Leydig cell tumour | 1 STG I   |                    |

S – seminoma; NS – non seminoma; Mx – mixt; Ter – teratoma; Ca Emb – embryonal carcinoma; Epid Cyst – epidermoid cyst; NED – no evidence of disease; DOD – dead of disease

with an overall survival of 100% (median follow-up 45.4 months, range 6–145). The 72.7% (8/11) of bilateral NS-GCT are stage III, with 62.5% (5/8) mortality for disease progression. The mixed form has a heterogeneous stage presentation: 44.4% (12/27) stage I, 29.6% (8/27) stage II, and 26% (7/27) stage III. Only one death for disease was reported in patients with stage III (seminoma + embryonal carcinoma).

**Results**

**Epidemiology and risk factors**

The incidence of testicular cancer appears to be increasing, while the age at which it develops seems to be decreasing [7, 19]. However, the causes of this trend remain unclear [20]. In the last two decades several studies reported an incidence of bilateral testicular cancer of between 2 and 5% [2, 3].

Synchronous bilateral tumours can be estimated to represent 0.5–1% of all new testicular cancer cases [3, 7].

Risk factors for bilateral testis cancer, either synchronous or metachronous, are the same as for testis cancer: atrophy of the testis, infertility, Klinefelter’s syndrome, a family history of testicular cancer, and a history of cryptorchidism or undescended testis (testicular dysgenesis syndrome) [21–23]. This risk is greater when two or more factors are present.

It was proposed that 25% to 33% of all patients have a genetic predisposition [24]. The influence of molecular and genetic risk factors has also not been established.
carcinoma [25]. Their migration and survival depends on the c-kit protein, a receptor protein kinase expressed in intratubular neoplastic germ cells and in seminoma. Two studies detected a point mutation in the c-kit codon 816 in the majority of the bilateral testis cancer [25, 26]. However, more recent reports are not in agreement with these early studies [19–28]. Other genetic changes, gene mutations on chromosomes 4, 5, 6, 9, 12, and 17, have been described in patients with testicular cancer [29–32].

The implication of these risk factors is not clear in patients with synchronous testis cancer, unless organ-preserving surgery is indicated. In this case we have to consider the presence of TIN (testicular intraepithelial neoplasia), now commonly known as intratubular germ cell neoplasia (ITGCN) [33, 34], or stem cell factor receptor c-KIT [25] in the surgical multiple biopsies taken from the remaining parenchyma, as some authors advise [35]. It is especially important to pay attention to the presence of ITGCN because it is considered a premalignant lesion. Its incidence is higher in patients with the same risk factors of bilateral testis cancer. In the literature it is well reported that if ITGCN is present on testicular biopsy and is left untreated, the developing risk of malignancies in the testis is 50% within five years and 70% within seven years [36]. Despite the fact that testicular biopsy in testis cancer is not routinely performed in clinical practice, it should be regularly considered in bilateral testis cancer and in cases of testis-sparing surgery [37].

However, it must be considered that treatment decisions for patients with synchronous tumours were formulated on the basis of risk stratification, as defined by the International Germ Cell Consensus Classification (IGCCCG) [38].

Treatment

Bilateral radical orchiectomy is considered the standard of care in cases of synchronous testis cancer with impaired pre-operative testosterone levels, when tumour volume is more than 30% of the testicular volume, in spite of collateral effects such as erectile dysfunction, infertility, and psychological distress. Furthermore, when testosterone concentration does not remain within the normal limit for endocrine failure, its lifelong substitution is mandatory [39].

Testis-sparing surgery has been developed as an alternative to radical orchiectomy, with the advantage that androgen production, body image, and fertility can all be preserved [40, 41].

In patients with bilateral testicular cancer Heidenreich et al. [42] described testis-sparing surgery to avoid lifelong androgen replacement and preserve fertility. Other authors report patients with a better quality of life and with a disease-free survival rate comparable with radical orchiectomy [17, 18, 43].

The surgical technique is nowadays codified [44]. Some authors suggest partial testicular resection in cold ischaemia [44, 45].

Organ preserving surgery can be performed if the tumour is < 2 cm in diameter, confined to the testis (or at least smaller than 30% of the testicular volume), and pre-operative serum levels of both testosterone and luteinising hormone (LH) are normal [46].

As previously declared, a major problem of this surgery is the presence of ITGCN in the adjacent parenchyma. Biopsy of the remaining parenchyma in all patients who have undergone conservative surgery is recommended to establish the presence of these premalignant lesions and multifocality of the tumours. In fact, ITGCN was proven as a risk factor to developing a tumour in 50% of men within 5 years [36]. Heidenreich et al. [45] reported the presence of TIN in 82% of 73 patients with bilateral or solitary tumour. All patients were treated with testis-sparing surgery and adjuvant scrotal radiotherapy (18 Gy). None of them had any sign of local relapse, with 85% of normal testosterone levels at long-term follow-up. Therefore, if ITGCN is discovered, irradiation therapy must be administrated, although the optimal radiotherapy schedule is still controversial. Currently the standard radiation dose is 20 Gy [47], with evidence of Leydig cell function being affected at doses of 14–20 Gy [48, 49]. A low radiation dose can compromise oncological outcome despite there having been few cases of radiation failure [48–52].

A survey of the German Testicular Cancer Study Group reported a 2.5% failure rate after radiotherapy with a 30.8% of post-treatment hypogonadism, even if 22% of them had received additional chemotherapy [53].

Giwcrcman et al. [54] reported no evidence of local recurrence after a median follow up period of 30 months (range 3–36) in patients treated with a 20-Gy schedule. Nevertheless, 25% of them required hormone supplementation because of Leydig cell dysfunction.

As an alternative to bilateral surgery, a recent report suggests that synchronous bilateral seminoma can be successfully treated with unilateral orchietomy for the larger tumour, followed by three courses of chemotherapy with cis-platinum, etoposide, and bleomycin [13]. However, this protocol, which must be considered as experimental, did not take into account that recurrence can be seen even after chemotherapy, which is inactive on intraepithelial neoplasia [53, 55]. This aspect is the major drawback and limitation of this study.

Furthermore, after organ-preserving surgery chemotherapy and radiation treatment can also impair fertility. In patients in the reproductive age group, if descendants are desired, pre-treatment fertility assessment (testosterone, LH, and follicle-stimulating hormone [FSH] levels) should be performed, and semen analysis and cryopreservation should be offered. If cryopreservation is desired, it should be preferably obtained before orchietomy, and in any case prior to chemotherapy treatment [56–58].

Hormonal replacement

In case of bilateral orchietomy or post-radio-chemotherapy damage of Leyding cells, testosterone substitution is important in an attempt to minimise the long-term adverse effects and risks associated with low levels of testosterone, such as osteoporosis. Furthermore, testosterone insufficiency in older men is associated with an increased risk of death over the subsequent 20 years [59]. Low testosterone levels have also been linked to metabolic
syndrome and type II diabetes, with both conditions being associated with cardiovascular disease, and shown to predict elevated overall and cardiovascular-related mortality in middle-aged and older men [60, 61].

For these reasons testosterone replacement is mandatory after bilateral orchiectomy. On the other hand, testosterone replacement causes polycythaemia and an increase in cardiac risk profile because of greater blood viscosity, changes in lipoproteins, and insulin resistance. Additionally, it is important to choose a suitable way of administration. In fact, oral testosterone is not recommended for complete hypogonadism, such as would occur after bilateral orchiectomy. Intramuscular testosterone injections frequently result in fluctuating levels of testosterone outside the physiological range at least 50% of the time, with serum testosterone levels that are initially supra-physiological and then sub-therapeutic. These abnormal testosterone serum levels cause a considerable variation in the scores for sexual functioning and physical well-being; furthermore, all patients found the injections tiresome and painful. Transdermal patches release testosterone more physiologically but can cause skin irritation, which is the main adverse effect, annoying enough to stop treatment in 10 to 50% [62–64]. Subcutaneously implanted testosterone pellets release testosterone slowly, thus achieving physiological testosterone levels for up to 4–6 months. Complications such as dislodgement and infection occur in 10% of cases, but patient acceptance is high.

Survival

With regard to oncological results, in a recent systematic review [65] the synchronous tumour had a lower five-year overall survival and five-year disease-specific survival than the metachronous tumour. At the statistical analysis the patients with a higher clinical stage and discordant histology had a worse prognosis, but when patients with the same clinical stage are compared, no difference in terms of five-year overall survival and five-year disease-specific survival was recorded between the two groups. However, these conclusions did not take into account the different histology of bilateral testis cancer. Considering previously reported series, patients with bilateral seminoma presented with a low stage at diagnosis and they had a good overall survival, whereas cases with bilateral NSGCT have poor prognosis and high stage at presentation.

The outcome of patients with advanced non-seminomatous synchronous bilateral testis cancer is dependent on IGCCCG prognostic categories. The presence of non-pulmonary visceral metastases, elevated tumour marker levels, vascular/lymphatic in- or peri-tumoural invasion, proliferation rate > 70%, and percentage of embryonal carcinoma > 50% are negative prognostic factors [38].

Follow-up

The follow-up schedule is the same for patients with unilateral testis cancer. Life-long follow-up may be advocated because of a small risk for late relapse. Close clinical control, with ultrasound of the testis, may therefore be recommended for patients undergoing testis-preserving surgery. Patients with SBTC must be followed-up not only for oncological issues but also for the risk of psychosocial and physical effects due to curative treatment (surgery alone or plus radio-chemotherapy) and hormonal replacement therapy [39, 66, 67].

In conclusion, with modern therapeutic options and the introduction of cis-platinum chemotherapy, most patients with synchronous bilateral testicular germ cell tumours will become long-term survivors with the same overall survival and disease specific survival than metachronous patients. Consequently, short- and long-term morbidity and psychosocial difficulties may become the major problems. Cancer can be cured in long-term survivors only if their quality of life after treatment can be restored to the previous level. Testis-sparing surgery must be performed whenever possible. Patients with germ cell tumours require a lifelong follow-up.

The authors declare no conflict of interest.

References

1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer Mortality in Europe, 2000-2004, and an overview of trends since 1995. Ann Oncol 2010; 21: 1323-60.
2. Akdogan B, Divrik RT, Tombul T, et al. Bilateral testicular germ cell tumors in Turkey: increase in incidence in last decade and evaluation of risk factors in 30 patients. J Urol 2007; 178: 129-33.
3. Klatte T, de Martino M, Arensmeier K, Reiter F, Allhoff EF Klatter D. Management and outcome of bilateral testicular germ cell tumors: A 25-year single center experience. Int J Urol 2008; 15: 821-6.
4. Holzebrerlein JM, Sogani PC, Sheinfeld J. Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: The Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol 2003; 169: 2122-5.
5. Fossa SD, Chen J, Schönfeld SJ, et al. Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men. J Natl Cancer Inst 2005; 97: 1056-66.
6. Dieckmann KP; Hamm B, Due W, Bauer HW. Simultaneous bilateral testicular germ cell tumors with dissimilar histology: case report and review of the literature. Urol Int 1988; 43: 305-9.
7. Ondrus D, Hoříčák M, Matoska J. Bilateral testicular germ-cell tumors – a single centre long-term experience. Int Urol Nephrol 2001; 33: 521-4.
8. Pharris-Ciurej ND, Cook LS, Weiss N. Incidence of testicular cancer in the United States: has the epidemic begun to abate? Am J Epidemiol 1999; 150: 45.
9. Hentrich M, Weber N, Bergsdorf T, Liedl B, Hartenstein R, Gerl A. Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. Acta Oncol 2005; 44: 529-36.
10. Coogan CL, Foster RS, Simmons GR, Tognoni PG, Roth BI, Donehue JP. Bilateral testicular tumors and management and outcomes in 21 patients. Cancer 1998; 83: 547.
11. Geczi L, Gomez F, Bak M, Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. J Cancer Res Clin Oncol 2003; 129: 309-15.
12. Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer 2002; 95: 1228-1233.
13. Tomita E, Kondo T, Nakazawa H, Ito F, Hashimoto Y, Tanabe K. Successful testis preservation for bilateral testicular tumors with
Synchronous bilateral testis cancer: clinical and oncological management

36. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE.
35. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis:
33. Bazzi WM, Raheem OA, Stroup SP, Kane CJ, Derweesh IH, Downs
32. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromo-
31. Gilbert D, Rapley E, Shipley J. Testicular germ cell tumours: pre-
30. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. Common variation in
28. Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur pre-
27. Rapley EA, Hockley S, Warren W, et al. Somatic mutations of KIT
26. Biermann K, Göke F, Nettersheim D, et al. c-KIT is frequently mu-
24. Nicholson PW and Harland SJ. Inheritance and testicular cancer. Br
21. Hotaling JM, Walsh TJ. Male infertility: a risk factor for testicular
20. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE.
18. Ferretti L, Sargos P, Gross-Goupil M, et al. Testicular-sparing sur-
16. Heidenreich A, Bonfig R, Derschum W, von Vietsch H, Wilbert DM.
14. Theodore C, Terrier-Lacombe MJ, Laplanche A, et al. Bilateral germ-
13. Stenwig AE, Sauter G, Fosse ES, et al. Long-term follow-up of bila-
12. Revised 1997 staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
11. Heidenreich A, Hofmann R. Quality of life in testicular cancer. World J Urol 1999; 17: 230-8.
10. Giannarini G, Dieckmann K, Albers P, Heidenreich A, Pizzocaro G. Organ-Sparing Surgery for Adult Testicular Tumours: A Systematic Review of the Literature. Eur Urol 2010; 57: 780-90.
9. Zumiga A, Lawrentschuk N, Jewett MA. Organ-sparing approaches for testicular masses. Nat Rev Urol 2010; 7: 454-64.
8. Heidenreich A, Holtl W, Albrecht W, Pont J, Engelmann UH. Test-
7. Heidenreich A, Angerer Shpieny M. Organ-preserving surgery for testicular tumours. BJU Int 2012; 109: 474-90.
6. Hallak G, Coruza M, Sarkis AS, Athayde KS, Cerri GG, Srougi M. Organ-sparing microsurgical resection of incidental testicular tumours plus microsuction for sperm extraction and cryopreservation in azoospermic patients: surgical aspects and technical refinements. Urology 2009; 73: 887-92.
5. Heidenreich A, Weissbach L, Holtl W, et al. Organ sparing surgery for malignant germ cell tumors of the testis. J Urol 2001; 166: 2161.
4. Albers P, Albrecht W, Albrecht W, et al. European Association of Urology. EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304-19.
3. Kregge S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 2008; 53: 478-96.
2. Petersen PM, Giwercman A, Daugaard G, et al. Effect of graded testicular dose of radiotherapy on patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002; 20: 1537-43.
1. Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G, Jorgensen N. Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 2009; 75: 672-6.
0. Dieckmann KP, Lauke H, Michl U, Winter E, Loy V. Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur J Urol 2002; 41: 643-9.
15. Hotaling JM, Walsh TJ. Male infertility: a risk factor for testicular cancer. Cancer 1997, 80: 1954-60.
14. Nicholson PW and Harland SJ. Inheritance and testicular cancer. Br J Cancer 1995; 71: 421
13. Biermann K, Göke F, Nettersheim D, et al. c-KIT is frequently mutated in bilateral germ cells tumors and down-regulated during progression from intratubular germ cell neoplasia to seminoma. J Pathol 2007; 213: 311-8.
12. Rapley EA, Hockley S, Warren W, et al. Somatic mutations of KIT in familial testicular germ cell tumors. Br J Cancer 2004; 14: 2397-401.
11. Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predomi-
nantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosomes Cancer 2008; 47: 34-42.
10. Rapley EA, Turnbull C, Al Olama AA, et al.; UK Testicular Cancer Collaboration. A genome-wide association study of testicular germ cell tumor. Nat Genet 2009; 41: 807-10.
9. Kanetsky PA, Mitra N, Vardhanabhuti S, et al. Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat Genet 2009; 41: 811-5.
8. Gilbert D, Rapley E, Shipley J. Testicular germ cell tumours: pre-
disposition genes and the male germ cell niche. Nat Rev Cancer 2011; 11: 278-88.
7. Draper JS, Smith K, Gokhale P, et al. Recurrent gain of chromo-
somes 17q and 12 in cultured human embryonic stem cells. Nature Biotech 2004; 22: 53-4.
6. Bazzi WM, Raheem OA, Stroup SP Kane CJ, Drwesw. IHH, Downes TM. Partial orchiectomy and testis intratubular germ cell neopla-
sia: World literature review. Urol Ann 2011; 3: 115-8.
5. Sharma P, Dhillon I, Sexton WJ. Intratubular germ cell neoplasia of the testis, bilateral testicular cancer, and aberrant histologies. Urol Clin North Am 2015; 42: 277-85.
4. Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: a review of biological and clinical features. Int J Cancer 1999; 83: 915-22.
3. Hoei-Hansen CE, Raptet-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tu-
mours: a clinical review. Ann Oncol 2005; 16: 863-8.
57. De Santis M, Albrecht W, Höltl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999; 83: 864-5.
58. Spermon JR, Kiemenej LA, Meuleman EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumours. Fertil Steril 2003; 79 (Suppl 3): 1543-9.
59. Laughiun GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
60. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 2008; 21: 24-36.
61. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009; 32: 587-98.
62. Parker S, Armitage M. Experience with transdermal testosterone replacement for hypo-gonadal men. Clin Endocrinol 1999; 50: 57-62.
63. Fossa SD, Opjordsmoen S, Haug E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer 1999; 35: 1220-5.
64. Gooren L, Mathijs CM. Androgen replacement therapy: present and future. Drugs 2004; 64: 1861-91.
65. Zequi S, da Costa W, Santana T, Favaretto R, Sacomani C, Guimaraes. Bilateral testicular germ cell tumours: a systematic review. BJU Int 2012; 110: 1102-9.
66. Mykletun A, Dahl AA, Haaland CF, et al. Side-effects and cancer related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 3061-8.
67. Abouassaly R, Fossa D, Giwercman A, et al. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol 2011; 60: 516-26.

Address for correspondence

Davide Campobasso
Urology OU, Civil Hospital of Guastalla
AUSL of Reggio Emilia
V. Donatori di Sangue 1, Guastalla 42016 (RE), Italy
tel. +393388220525
e-mail: d.campobasso@virgilio.it

Submitted: 28.10.2015
Accepted: 22.06.2016